Title:
RECOMBINANT ONCOLYTIC VIRUS AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2024/012277
Kind Code:
A1
Abstract:
Provided are a recombinant oncolytic virus and the use thereof. The recombinant oncolytic virus comprises an M protein and a cytokine encoded by an exogenous gene. Compared with the amino acid sequence as shown in SEQ ID NO. 1, the M protein comprises the following site mutations: methionine at position 51 is mutated into arginine (M51R); valine at position 221 is mutated into phenylalanine (V221F); and serine at position 226 is mutated into arginine (S226R). The provided recombinant oncolytic virus has a good infection ability and in-vitro killing ability on dysproliferative (tumor) LLC cells, 4T1 cells, MC38 cells and Hela cells, and is not easy to clear from LLC cells, 4T1 cells, MC38 cells, and Hela cells, thereby having a greatly reduced infection ability on normal cells.
Inventors:
ZHOU GUOQING (CN)
ZHANG FAN (CN)
MA LIANG (CN)
TIAN TING (CN)
ZHANG FAN (CN)
MA LIANG (CN)
TIAN TING (CN)
Application Number:
PCT/CN2023/105011
Publication Date:
January 18, 2024
Filing Date:
June 30, 2023
Export Citation:
Assignee:
JOINT BIOSCIENCES SH LTD (CN)
International Classes:
C12N7/01; A61K35/766; A61P35/00; C07K7/04; C07K14/145
Domestic Patent References:
| WO2022057904A1 | 2022-03-24 |
Foreign References:
| CN111286493A | 2020-06-16 | |||
| CN114540316A | 2022-05-27 | |||
| CN111467489A | 2020-07-31 | |||
| CN109312366A | 2019-02-05 | |||
| CN110305198A | 2019-10-08 | |||
| US20210171583A1 | 2021-06-10 |
Attorney, Agent or Firm:
BEIJING WEIZHENG PATENT AGENCY CO., LTD. (CN)
Download PDF:
Previous Patent: CARRIER SWITCHING METHOD AND APPARATUS
Next Patent: RECOMBINANT ONCOLYTIC VIRUS AND USE THEREOF
Next Patent: RECOMBINANT ONCOLYTIC VIRUS AND USE THEREOF